RESEARCH MONOGRAPH · KDC-MN-102

NMN (Nicotinamide Mononucleotide)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

75/100

NAD+ precursor with real biology and an oral bioavailability question that's still partly open

NMN sits in an awkward spot. The NAD+ biology is real, the age-associated NAD+ decline is well-documented, and the mouse work from Imai, Sinclair, and others showed clear restoration of NAD+ levels and downstream phenotypic improvements in aged animals. Whats less clear is what happens with oral NMN in humans.

The big open question for years was whether NMN gets absorbed intact or whether it gets dephosphorylated to nicotinamide riboside (NR) in the gut, then transported across enterocytes, then re-phosphorylated to NMN intracellularly. The Slc12a8 transporter paper from Yoshino 2019 in Nature Metabolism claimed direct NMN transport, then Schmidt and Brenner 2019 pushed back hard, and the literature settled into a position where most NMN probably gets handled as NR-equivalent through CD73-mediated dephosphorylation. Practically, oral NMN raises whole-blood NAD+ in human trials (Yoshino, Yamaguchi, and others), so the endpoint people care about does respond.

Human trials are accumulating. The Igarashi 2022 Japanese trial showed measurable NAD+ elevation in older adults, the Yi 2023 trial showed walking endurance changes, and a handful of smaller studies show muscle and metabolic endpoints moving modestly. Effects are real but the magnitudes are typically modest compared to the rodent data, which is consistent with the broader pattern that NAD+ restoration in younger or non-deficient subjects yields less dramatic results.

What we like: NAD+ biology is one of the better-developed aging axes, the precursor strategy is mechanistically clean, and combination work with sirtuin activators or with senolytics or with rapamycin is where the interesting research is. The price has come down a lot from where it was five years ago.

What we dont like is the regulatory drama around NMN in the US (FDA's stance has bounced around), the persistent confusion about NMN vs NR positioning, and the wishful thinking that oral NMN restores youth. It restores NAD+, modestly, and downstream effects are real but moderate.

Sourcing: this is where it gets serious. Quality NMN is HPLC 98%+ and ideally also NAD+ purity tested, not just by mass. There's a lot of NMN on the market that's been adulterated with cheaper nicotinamide. Reputable suppliers with COAs are essential. Stability is decent if kept cool and dry.

Real molecule, real biology, dont oversell what's been demonstrated in humans yet.

Evidence: 65
Mechanism: 80
Reliability: 70
Safety: 85
Sourcing: 75
Value: 70
Signal: 75
Staying power: 78

Plain-language summary Intrigue 72 / 100

NMN is a direct precursor to NAD+, the central energy cofactor that declines with age. Supplementation aims to restore youthful NAD+ levels. David Sinclair's lab has been the most prominent in advancing NMN research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

NAD+ precursor

A direct precursor of NAD+ and the molecule directly downstream of NAMPT, the rate-limiting enzyme of NAD+ salvage; popularized by David Sinclair for longevity applications.

Abstract

NMN (β-nicotinamide mononucleotide; CAS 1094-61-7; molecular formula C11H15N2O8P; molecular weight 334.22) is the immediate precursor of NAD+ in the salvage biosynthesis pathway, generated by phosphorylation of nicotinamide riboside by NRK kinases or by NAMPT-mediated condensation of nicotinamide with PRPP. NMN was popularized by David Sinclair's group at Harvard as a longevity supplement for raising NAD+ levels, which decline with age. The compound is converted to NAD+ through NMNAT enzymes after cell uptake (presumed via Slc12a8 transporter or via dephosphorylation to NR with separate uptake). Animal studies show NMN supplementation reverses several age-related phenotypes (vascular, metabolic, neurological) by restoring NAD+ levels. Human clinical trials have shown plasma NAD+ elevation but clinical endpoint changes are modest. The compound is sold as a dietary supplement; FDA classified NMN as a drug investigation in 2022, complicating supplement market availability. Reported research dose ranges in the literature are typically 250 to 1000 mg.

Mechanism of action

Direct NAD+ precursor; converted to NAD+ via NMNAT after cellular uptake.

Reported research dose ranges

250 to 1000 mg (reported research dose ranges in the literature).

References

Yoshino J, et al. NAD intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 2018.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-102

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

NMN (Nicotinamide Mononucleotide)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs